AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud

Three months after regulators at the FDA forced AbbVie to halt enrolling patients in its trials of a combination using Venclexta (venetoclax) to treat drug-resistant cases of multiple myeloma, the agency has green-lighted the resumption of one of those studies, while keeping the rest on the sidelines.